Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BioNTech News

Ghko B 2025 Sep 18, 16:00

Dow, S&P 500, Nasdaq hit records: INTC stock surges 22%, NVDA stock up 3.5%

stocks indices
Ghko B 2025 Sep 18, 16:00

Official Trump Price Prediction: Is Trump Crypto Coin Expected to Go Up?

crypto
Ghko B 2025 Sep 18, 16:00

Plug Power Stock Forecast: NASDAQ: PLUG Stock Soared 5%, What’s next?

stocks
Frances Wang 2025 Sep 17, 16:00

Aramco Stock Jumps over 3%: Why Aramco Stock Is Trading Higher Today?

stocks
Ghko B 2025 Sep 17, 16:00

Best Growth Stocks to Watch 2025: TSLA, NVDA, NIO Stock, AMD

stocks
Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Latest news

Show more
Sophia Claire 2025 Sep 19, 04:20

Bank of Japan Holds Rates Steady, Plans to Start Selling ETFs

Liam James 2025 Sep 18, 15:20

Hong Kong Gold Theft Recovered: A Sign of a Growing Global Trend?

Ava Grace 2025 Sep 18, 15:20

US Initial Jobless Claims Fall: A Rebound or a Sign of Stability?

Sophia Claire 2025 Sep 18, 14:20

White House Reacts to Fed Rate Cut: Implications and Analysis

Sophia Claire 2025 Sep 18, 13:20

Swiss Gold Exports to US Plunge Amid Tariff Confusion

Sophia Claire 2025 Sep 18, 12:20

BOJ Rate Hike Speculation Amidst Political Shifts: An October Surprise?

Noah Lee 2025 Sep 18, 11:20

Bank of England Holds Rates, Cautions on Inflation: Market Analysis

Ava Grace 2025 Sep 18, 10:20

Trump-UAE Deals: AI Chips and Investments Spark Controversy

Info

Spread

0.7178

Spread (%)

0.7482 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Friday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

23152799744

Shares Outstanding

240398724

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-1.7

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Frances Wang 2025 Sep 17, 16:00

Stock market outlook: what’s the target price for Saudi Tadawul Gr stock?

Stocks
Frances Wang 2025 Sep 17, 16:00

Gold Trading in Saudi Arabia: Beginners Guide to XAU/USD CFD Trading

Commodities
Ghko B 2025 Sep 17, 16:00

CFD Trading for Beginners: Why CFD Trading Is Popular in the Middle East?

CFD Trading
Trustpilot